Vyvanse

ADHD.

Adult & ped patient ≥6 yr Initially 30 mg once daily in the morning, may be adjusted in increments of 10 mg or 20 mg at approx wkly intervals. Max dose: 70 mg once daily. Patient w/ severe renal impairment (GFR 15 to <30 mL/min/1.73 m²) Max dose: 50 mg once daily. Patient w/ ESRD (GFR <15 mL/min/1.73 m²) Max dose: 30 mg once daily.

May be taken with or without food: Swallow whole. Alternatively, open cap, empty & mix entire contents w/ yogurt, water, or orange juice until completely dispersed, then consume entire mixt immediately. Do not divide a single dose.

Hypersensitivity to amphetamine products. Patients taking MAOIs or w/in 14 days of stopping MAOIs (including linezolid or IV methylene blue).

Not indicated or recommended for wt loss. Avoid afternoon doses because of the potential for insomnia. High potential for abuse & dependence. Assess risk of abuse prior to prescribing, & monitor for signs of abuse & dependence while on therapy. Risk of serious CV reactions. Avoid use in patients w/ known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, CAD, & other serious heart problems. Assess for presence of cardiac disease prior to treatment initiation. Risk of increased BP & heart rate. Monitor for potential tachycardia & HTN. May exacerbate symptoms of behavior disturbance & thought disorder in patients w/ pre-existing psychotic disorder. May induce a mixed/manic episode in patients w/ bipolar disorder. May cause psychotic or manic symptoms in patients w/o prior history of psychotic illness or mania. Associated w/ wt loss & slowing of growth rate in ped patients. Closely monitor growth (wt & height) in ped patients on treatment. Associated w/ peripheral vasculopathy, including Raynaud's phenomenon. Carefully observe for digital changes during treatment. Immediately discontinue treatment w/ Vyvanse & any concomitant serotonergic agents if symptoms of serotonin syndrome occur. Reduced clearance in patients w/ severe renal impairment or ESRD. Not dialyzable. May decrease placental perfusion during pregnancy. Increased risk of premature delivery & low birth wt in infants born to amphetamine-dependent mothers. Monitor infants for w/drawal symptoms eg, feeding difficulties, irritability, agitation, & excessive drowsiness. Breastfeeding is not recommended during treatment. Not approved for use in ped patients <6 yr.

Anorexia, anxiety, decreased appetite/wt, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting.

Slowed metabolism & increased effect w/ MAOIs. Increased risk of serotonin syndrome w/ serotonergic drugs. Increased exposure w/ CYP2D6 inhibitors. Increased blood levels & potentiated action w/ urinary alkalinizing agents. Decreased blood levels & efficacy w/ urinary acidifying agents. Increased brain conc & potentiated CV effects w/ TCAs.

Other CNS Drugs & Agents for ADHD

N06BA12 - lisdexamfetamine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.

P₁S₁S₃